<DOC>
	<DOCNO>NCT01760109</DOCNO>
	<brief_summary>In propose study , investigator plan evaluate efficacy safety Piperacillin Sodium Sulbactam Sodium Injection ( 2:1 ) treatment respiratory urinary tract acute bacterial infection .</brief_summary>
	<brief_title>Piperacillin Sodium Sulbactam Sodium Injection ( 2:1 ) Treatment Respiratory Urinary System Infection</brief_title>
	<detailed_description>Piperacillin sodium sulbactam sodium injection ( 2:1 ) play therapeutic role former inhibit bacterial cell wall synthesis，the latter make irreversible competitive inhibition β-lactamase.The antimicrobial effect Piperacillin enhance two combine . The compound specifically aim mechanism bacterial resistance , extend life Piperacillin treatment-resistant pathogen infection .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<criteria>1. patient qualify moderate severe acute respiratory urinary tract bacterial infection acute bacterial infection need systemic antibiotic therapy . 2 . Age &gt; 18 year old , Gender : 3 . Women childbearing age negative pregnancy test agree take contraceptive measure trial ; 4. patient volunteer sign informed consent form ; 5. patient participate clinical trial . 1 . Patients hypersusceptibility test drug penicillin , βlactamase inhibitor 2 . Pregnant Lactating woman 3 . Patients severe liver , kidney , cardiovascular , cerebrovascular , endocrine hematopoietic system primary disease immunodeficiency , advance cancer mental illness . 4 . Patients complicate disease think affect efficacy evaluation poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Respiratory urinary tract infection</keyword>
	<keyword>Piperacillin Sodium Sulbactam Sodium Injection ( 2:1 )</keyword>
	<keyword>Phase IV</keyword>
</DOC>